Skip to content
Home/Companies/Biotech/ProQR Therapeutics
ProQR Therapeutics

ProQR Therapeutics

Biotech·Netherlands·Active·8yr hold
Entry
2018
Hold
8yr
Status
Active

Who owns ProQR Therapeutics?

ProQR Therapeutics is a Dutch Biotech company, currently owned by Sofinnova Partners since 2018.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital IX · 2018 · Life Sciences VC

Key facts

HQNetherlands
SectorBiotech
Websitewww.proqr.com

More from Sofinnova Capital IX

Other portfolio companies in the same fund.

Asceneuron
Active
BiotechSwitzerland· 2020
CorVent Medical
CorVent Medical
Active
MedTechUS· 2020
Genespire
Genespire
Active
BiotechItaly· 2020
Nitrase Therapeutics
Nitrase Therapeutics
Active
BiotechUS· 2020
Noema Pharma
Noema Pharma
Exited 2022
BiotechSwitzerland· 2020
to NOEMA PHARMA SA
Pi-Cardia
Pi-Cardia
Active
MedTechIsrael· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns ProQR Therapeutics?

ProQR Therapeutics is currently owned by Sofinnova Partners, through Sofinnova Capital IX, since 2018.

When did Sofinnova Partners acquire ProQR Therapeutics?

Sofinnova Partners acquired ProQR Therapeutics in 2018.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue